SCHEMBL4818608

SCHEMBL4818608

COC(=O)c1ccc(-c2cc(NC(=O)OC(C)(C)C)ccc2C)cc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 3/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA9 Q16790 1/20 0.46
KMT2A Q03164 3/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
MAPK14 Q16539 6/20 0.43
MAPT P10636 2/20 0.43
ALDH1A1 P00352 1/20 0.43
LCK P06239 1/20 0.42
PTPN1 P18031 1/20 0.42
MEN1 O00255 2/20 0.41
EGFR P00533 1/20 0.41
PSMB8 P28062 1/20 0.41
NAMPT P43490 1/20 0.41
SLC2A1 P11166 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4822293 0.95 CYP17A1 (0.43) CYP17A1CA12CA1CA9KMT2A
SCHEMBL2349306 0.89 PDK1 (0.46) CYP17A1CA12CA1CA9KMT2A
SCHEMBL2347126 0.89 CYP17A1 (0.47) CYP17A1CA12CA1CA9MAPK14
SCHEMBL18165108 0.85 CA12 (0.48) CYP17A1CA12CA1CA9PSMB8
SCHEMBL5544961 0.84 CYP17A1 (0.61) CYP17A1KMT2AMAPTALDH1A1PTPN1
SCHEMBL4315966 0.82 MEN1 (0.59) CYP17A1KMT2AMAPTALDH1A1PTPN1
SCHEMBL13586831 0.81 MAPK14 (0.45) KMT2ACTDSP1MAPK14MAPTALDH1A1
SCHEMBL4818740 0.79 MAPK14 (0.74) MAPK14
SCHEMBL1530721 0.79 CYP17A1 (0.41) CYP17A1CA1KMT2ACTDSP1MAPT
SCHEMBL507957 0.79 CA12 (0.52) CYP17A1CA12CA1CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7626055-B2 Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-12-01 US disclosed
US-7432289-B2 5-Acylamino-1,1′-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2008-10-07 US disclosed
US-7432289-B2 5-Acylamino-1,1′-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2008-10-07 US disclosed
US-7432289-B2 5-Acylamino-1,1′-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2008-10-07 US disclosed
EP-1436272-B1 BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS GLAXO GROUP LTD (GB) 2008-05-07 EP disclosed
US-7309800-B2 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2007-12-18 US disclosed
US-7309800-B2 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2007-12-18 US disclosed
US-7271289-B2 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2007-09-18 US disclosed
US-7271289-B2 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2007-09-18 US disclosed
US-20070142476-A1 Biphenyl-Derivatives as p38 Kinase Inhibitors GLAXO GROUP LIMITED 2007-06-21 US disclosed
US-20070105850-A1 Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2007-05-10 US disclosed
US-20070105860-A1 Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors GLAXO GROUP LIMITED 2007-05-10 US disclosed
US-20070105860-A1 Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors GLAXO GROUP LIMITED 2007-05-10 US disclosed
EP-1611085-B1 BIPHENYL-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2007-02-28 EP disclosed
US-7183297-B2 Biphenyl-derivatives as p38-kinase inhibitors GLAXO GROUP LIMITED (GB) 2007-02-27 US disclosed
US-7183297-B2 Biphenyl-derivatives as p38-kinase inhibitors GLAXO GROUP LIMITED (GB) 2007-02-27 US disclosed
US-20040242868-A1 5-acylamino-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2004-12-02 US disclosed
EP-1435934-A1 5'-ACYLAMINO-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-07-14 EP disclosed
WO-2003032971-A1 5’-ACYLAMINO-1,1’-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142476-A1 Biphenyl-Derivatives as p38 Kinase Inhibitors MAPK1, MAPKAPK2, MAPK3 CYP17A1 630/4885CA12 4873/4885CA1 4730/4885
US-20040242868-A1 5-acylamino-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors MAPK1, MAP3K1, MAPK7 CYP17A1 2044/4885CA12 4763/4885CA1 3606/4885
US-20070105860-A1 Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors MAPK1, MAPKAPK2, MAPK3 CYP17A1 1758/4885CA12 4725/4885CA1 4063/4885
US-20070105850-A1 Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors MAPK1, MAPKAPK2, MAP3K8 CYP17A1 1767/4885CA12 4781/4885CA1 4612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.